FDA-cleared profile

HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

Samsung Medison CO., LTD. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: The HERA W9 and HERA W10 diagnostic ultrasound systems and transducers provide diagnostic ultrasound imaging and fluid analysis across the labeled fetal, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel applications under appropriately trained healthcare-professional supervision.

Clinical role
Diagnostic ultrasound imaging, fluid analysis, measurement, display, and analysis using the exact labeled probes and modes.
Images and patients
Ultrasound · Fetal/obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel anatomy
Key limitation
Keep in mind: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The HERA W9 and HERA W10 diagnostic ultrasound systems and transducers provide diagnostic ultrasound imaging and fluid analysis across the labeled fetal, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel applications under appropriately trained healthcare-professional supervision.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal/obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel anatomy Input: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
  • Who uses it?Intended users: Appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound equipment.
  • What does the software produce?Output: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
  • What is its most important limitation?Key limitation: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.

Clinical takeaway. Clinical role: The HERA W9 and HERA W10 diagnostic ultrasound systems and transducers provide diagnostic ultrasound imaging and fluid analysis across the labeled fetal, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel applications under appropriately trained healthcare-professional supervision.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus deep learning validation: segmentation on 320 fetal biometry images from two hospitals (average dice-score 0.91, threshold 0.8) and view recognition on 1,320 fetal heart and fetal biometry images (average recognition accuracy 94.70%, threshold 89%; segmentation dice-score 0.875), with views classified by three experts and anatomy manually drawn; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The HERA W9 and HERA W10 diagnostic ultrasound systems and transducers provide diagnostic ultrasound imaging and fluid analysis across the labeled fetal, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel applications under appropriately trained healthcare-professional supervision.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Diagnostic ultrasound imaging, fluid analysis, measurement, display, and analysis using the exact labeled probes and modes.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital, clinic, private practice, emergency, operating-room, or other labeled clinical environment.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound equipment.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus deep learning validation: segmentation on 320 fetal biometry images from two hospitals (average dice-score 0.91, threshold 0.8) and view recognition on 1,320 fetal heart and fetal biometry images (average recognition accuracy 94.70%, threshold 89%; segmentation dice-score 0.875), with views classified by three experts and anatomy manually drawn; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety, and has been found to conform with applicable medical device safety standards." … "A deep learning based segmentation algorithm was validated using 320 fetal biometry images collected at two hospitals (South Korea and United States). ◌ The average dice-score is 0.91 (threshold 0.8)". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus deep learning validation: segmentation on 320 fetal biometry images from two hospitals (average dice-score 0.91, threshold 0.8) and view recognition on 1,320 fetal heart and fetal biometry images (average recognition accuracy 94.70%, threshold 89%; segmentation dice-score 0.875), with views classified by three experts and anatomy manually drawn; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety, and has been found to conform with applicable medical device safety standards." … "A deep learning based segmentation algorithm was validated using 320 fetal biometry images collected at two hospitals (South Korea and United States). ◌ The average dice-score is 0.91 (threshold 0.8)". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K230084

  • DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K230084; this is regulatory evidence, not an independent clinical effectiveness study.
  • PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K230084; a broader clinical population is not established here.
  • Scopeexact submission
  • Tested versionHERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System (K230084)
  • IndependenceSponsor or vendor study

K230084

The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K230084: HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K230084: HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K230084: HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
Samsung Healthcare USA's security advisories page, published under Boston Imaging (a Samsung company), posts vulnerability impact analyses and patch process statements for Samsung computed tomography, ultrasound and digital radiography modalities (including Log4j, Urgent11, BlueKeep and WannaCry analyses).
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: owning-domain press releases on usa.samsunghealthcare.com state that Boston Imaging is Samsung Medison's U.S. medical imaging business (unified as Samsung HME America, March 2026) and that Samsung Medison is an affiliate of Samsung Electronics. Corporate program statement; exact-release scope is not established.

Monitoring
Samsung Healthcare USA's security advisories page (Boston Imaging, a Samsung company) publishes product impact analyses and a patch process for Samsung CT, ultrasound and digital radiography modalities, with published advisories for Log4j, Urgent11, BlueKeep and WannaCry.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Samsung Healthcare USA / Boston Imaging generally and does not scope this process to any specific product release; exact-release scope is not established.

Workflow role

Diagnostic ultrasound imaging, fluid analysis, measurement, display, and analysis using the exact labeled probes and modes.

exact submission · checked 2026-09-04

Submission-anchored workflow summary, not a local acceptance or deployment result.

Input

Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.

exact submission · checked 2026-09-04

Output review, editing, approval, export, and downstream use remain release- and site-specific.

Deployment evidence

Exact deployment topology and operational boundaries remain unestablished.

exact submission · checked 2026-09-04

Confirm hosting, PHI flow, retention, access, updates, downtime, and support obligations before procurement or clinical use.

Integration evidence

Exact local interfaces, identity matching, routing, display, reporting, and fallback behavior remain unestablished.

exact submission · checked 2026-09-04

Validate the local workflow against the exact release and enabled options.

Vendor family context

Current vendor material is product-family context for K230084 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230084
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Fetal/obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, and peripheral-vessel anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-04-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K230084: HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

    U.S. Food and Drug Administration - Published 2023-04-21 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Samsung ultrasound family context

    Samsung Healthcare - Accessed 2026-09-04

    Scope: productFamilyContext

  8. Samsung Healthcare USA: Security Advisory

    Boston Imaging (Samsung) - Accessed 2026-10-26

    Scope: security

Research history

  1. K230084 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260844

ACUSON Sequoia Diagnostic Ultrasound System;ACUSON Sequoia Select Diagnostic Ultrasound System;ACUSON Origin Diagnostic Ultrasound System;ACUSON Origin ICE Diagnostic Ultrasound System

Siemens Medical Solutions USA, Inc.

Authorized purpose: ACUSON Sequoia, Select, Origin, and Origin ICE diagnostic ultrasound systems acquire and display the labeled fetal, abdominal, pediatric, neonatal, cephalic, small-part, obstetric, cardiac, transesophageal, intracardiac, vascular, and musculoskeletal examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; transesophageal and intracardiac applications
Decision
2026-06-16
FDA-cleared K260300

WatchMate Software

Anumana, Inc.

Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.

Modality
Ultrasound
Anatomy
Heart and left atrial appendage
Decision
2026-06-15
FDA-cleared K260780

HeartFocus

Deski

Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-06-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history